Journal of Clinical Endocrinology & Metabolism, Vol 81, 1736-1739, Copyright © 1996 by Endocrine Society

ARTICLES

Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study

ED Hsi, LR Zukerberg, WI Yang and A Arnold
Department of Pathology, University of Michigan, Ann Arbor 48109, USA.

The cyclin D1 (PRAD1) oncogene is rearranged with the PTH gene and is transcriptionally activated in a subset of parathyroid adenomas. Because of heterogeneity in rearrangement breakpoints, the true percentage of adenomas with cyclin D1 deregulation is unknown. Overexpression of the cyclin D1 protein in parathyroid adenomas appears to be a unifying consequence of all cyclin D1 gene rearrangements and can, therefore, be examined to more comprehensively identify adenomas in which cyclin D1 is pathogenetically important. We studied cyclin D1 expression in 65 parathyroid adenomas (from 64 patients), 51 normal parathyroid glands (from the same patients), and 4 parathyroid carcinoma specimens (from 3 patients) using a microwave-enhanced immunohistochemical method and affinity-purified cyclin D1 polyclonal antiserum. When available, data on adenoma mass, intact PTH level, and concurrent serum calcium level were also collected. Twelve of the 65 adenomas (18%) showed diffuse nuclear staining of approximately 30-70% of the tumor cells. All 51 normal glands were negative, except 1 gland that showed scattered cells ( < 10%) with positive nuclear staining. In addition, scattered positive cells were seen in the compressed rim of histologically normal parathyroid tissue surrounding 2 adenomas that were cyclin D1 negative. No significant differences in adenoma mass, intact PTH levels, or concurrent calcium levels were found between positive and negative tumors. Two of 4 parathyroid carcinoma specimens from 2 of 3 patients showed strong nuclear staining for cyclin D1. Overexpression of the cyclin D1 oncogene in 18% of our cases, due to the cyclin D1/PTH translocation and/or other mechanisms, suggests that overexpressed cyclin D1 plays a role in the pathogenesis of a much larger proportion of parathyroid adenomas than previously appreciated. Cyclin D1 overexpression is a feature of typical parathyroid adenomas and is not confined to unusually large, symptom-causing adenomas as had been suggested by early DNA studies. Although only three patients with parathyroid carcinoma were studied, two of the patients' tumors stained for cyclin D1, raising the possibility that the frequency of cyclin D1 overexpression may be even greater in carcinomas. Cyclin D1 overexpression appears to highlight a central pathway in parathyroid neoplasia.

This article has been cited by other articles:

				P. Bjorklund, G. Akerstrom, and G. Westin Accumulation of Nonphosphorylated {beta}-Catenin and c-myc in Primary and Uremic Secondary Hyperparathyroid Tumors J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 338 - 344. [Abstract] [Full Text] [PDF]

				B. S. Soares, K. Eguchi, and L. A. Frohman Tumor Deletion Mapping on Chromosome 11q13 in Eight Families with Isolated Familial Somatotropinoma and in 15 Sporadic Somatotropinomas J. Clin. Endocrinol. Metab., December 1, 2005; 90(12): 6580 - 6587. [Abstract] [Full Text] [PDF]

				G. J. Strewler A 64-Year-Old Woman With Primary Hyperparathyroidism JAMA, April 13, 2005; 293(14): 1772 - 1779. [Full Text] [PDF]

				L. Forsberg, E. Bjorck, J. Hashemi, J. Zedenius, A. Hoog, L.-O. Farnebo, M. Reimers, and C. Larsson Distinction in gene expression profiles demonstrated in parathyroid adenomas by high-density oligoarray technology Eur. J. Endocrinol., March 1, 2005; 152(3): 459 - 470. [Abstract] [Full Text] [PDF]

				X. Zhang, J. P. Gaspard, Y. Mizukami, J. Li, F. Graeme-Cook, and D. C. Chung Overexpression of Cyclin D1 in Pancreatic {beta}-Cells In Vivo Results in Islet Hyperplasia Without Hypoglycemia Diabetes, March 1, 2005; 54(3): 712 - 719. [Abstract] [Full Text] [PDF]

				M. Fu, C. Wang, Z. Li, T. Sakamaki, and R. G. Pestell Minireview: Cyclin D1: Normal and Abnormal Functions Endocrinology, December 1, 2004; 145(12): 5439 - 5447. [Abstract] [Full Text] [PDF]

				F. Cetani, E. Pardi, S. Borsari, P. Viacava, G. Dipollina, L. Cianferotti, E. Ambrogini, E. Gazzerro, G. Colussi, P. Berti, et al. Genetic Analyses of the HRPT2 Gene in Primary Hyperparathyroidism: Germline and Somatic Mutations in Familial and Sporadic Parathyroid Tumors J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5583 - 5591. [Abstract] [Full Text] [PDF]

				H. Sowa, H. Kaji, R. Kitazawa, S. Kitazawa, T. Tsukamoto, S. Yano, T. Tsukada, L. Canaff, G. N. Hendy, T. Sugimoto, et al. Menin Inactivation Leads to Loss of Transforming Growth Factor {beta} Inhibition of Parathyroid Cell Proliferation and Parathyroid Hormone Secretion Cancer Res., March 15, 2004; 64(6): 2222 - 2228. [Abstract] [Full Text] [PDF]

				O. Kifor, I. Kifor, F. D. Moore Jr., R. R. Butters Jr., T. Cantor, P. Gao, and E. M. Brown Decreased Expression of Caveolin-1 and Altered Regulation of Mitogen-Activated Protein Kinase in Cultured Bovine Parathyroid Cells and Human Parathyroid Adenomas J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4455 - 4464. [Abstract] [Full Text] [PDF]

				V M Howell, C J Haven, K Kahnoski, S K Khoo, D Petillo, J Chen, G J Fleuren, B G Robinson, L W Delbridge, J Philips, et al. HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours J. Med. Genet., September 1, 2003; 40(9): 657 - 663. [Abstract] [Full Text] [PDF]

				S. M. Mallya, J. J. Gallagher, and A. Arnold Analysis of Microsatellite Instability in Sporadic Parathyroid Adenomas J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1248 - 1251. [Abstract] [Full Text] [PDF]

				E. Szabo, T. Carling, O. Hessman, and J. Rastad Loss of Heterozygosity in Parathyroid Glands of Familial Hypercalcemia with Hypercalciuria and Point Mutation in Calcium Receptor J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3961 - 3965. [Abstract] [Full Text] [PDF]

				Y. Imanishi, H. Tahara, N. Palanisamy, S. Spitalny, I. B. Salusky, W. Goodman, M. L. Brandi, T. B. Drueke, E. Sarfati, P. Urena, et al. Clonal Chromosomal Defects in the Molecular Pathogenesis of Refractory Hyperparathyroidism of Uremia J. Am. Soc. Nephrol., June 1, 2002; 13(6): 1490 - 1498. [Abstract] [Full Text] [PDF]

				S. Hemmer, V.-M. Wasenius, C. Haglund, Y. Zhu, S. Knuutila, K. Franssila, and H. Joensuu Deletion of 11q23 and Cyclin D1 Overexpression Are Frequent Aberrations in Parathyroid Adenomas Am. J. Pathol., April 1, 2001; 158(4): 1355 - 1362. [Abstract] [Full Text] [PDF]

				E. Shane Parathyroid Carcinoma J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 485 - 493. [Full Text]

				Y. Kanesaka, H. Tokunaga, K. Iwashita, S. Fujimura, S. Naomi, and K. Tomita Endothelin Receptor Antagonist Prevents Parathyroid Cell Proliferation of Low Calcium Diet-Induced Hyperparathyroidism in Rats Endocrinology, January 1, 2001; 142(1): 407 - 413. [Abstract] [Full Text] [PDF]

				S. J. Marx Hyperparathyroid and Hypoparathyroid Disorders N. Engl. J. Med., December 21, 2000; 343(25): 1863 - 1875. [Full Text] [PDF]

				H. Tahara, Y. Imanishi, T. Yamada, Y. Tsujimoto, T. Tabata, T. Inoue, M. Inaba, H. Morii, and Y. Nishizawa Rare Somatic Inactivation of the Multiple Endocrine Neoplasia Type 1 Gene in Secondary Hyperparathyroidism of Uremia J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4113 - 4117. [Abstract] [Full Text]

				R. G. Pestell, C. Albanese, A. T. Reutens, J. E. Segall, R. J. Lee, and A. Arnold The Cyclins and Cyclin-Dependent Kinase Inhibitors in Hormonal Regulation of Proliferation and Differentiation Endocr. Rev., August 1, 1999; 20(4): 501 - 534. [Abstract] [Full Text] [PDF]

				N. Palanisamy, Y. Imanishi, P. H. Rao, H. Tahara, R. S. K. Chaganti, and A. Arnold Novel Chromosomal Abnormalities Identified by Comparative Genomic Hybridization in Parathyroid Adenomas J. Clin. Endocrinol. Metab., May 1, 1998; 83(5): 1766 - 1770. [Abstract] [Full Text]

				A. M. Parfitt, Q. Wang, and S. Palnitkar Rates of Cell Proliferation in Adenomatous, Suppressed, and Normal Parathyroid Tissue: Implications for Pathogenesis J. Clin. Endocrinol. Metab., March 1, 1998; 83(3): 863 - 869. [Abstract] [Full Text]